Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Published:2013-02 Issue:2 Volume:14 Page:149-158
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Gravis Gwenaelle,Fizazi Karim,Joly Florence,Oudard Stéphane,Priou Franck,Esterni Benjamin,Latorzeff Igor,Delva Remy,Krakowski Ivan,Laguerre Brigitte,Rolland Fréderic,Théodore Christine,Deplanque Gael,Ferrero Jean Marc,Pouessel Damien,Mourey Loïc,Beuzeboc Philippe,Zanetta Sylvie,Habibian Muriel,Berdah Jean François,Dauba Jerome,Baciuchka Marjorie,Platini Christian,Linassier Claude,Labourey Jean Luc,Machiels Jean Pascal,El Kouri Claude,Ravaud Alain,Suc Etienne,Eymard Jean Christophe,Hasbini Ali,Bousquet Guilhem,Soulie Michel

Publisher

Elsevier BV

Subject

Oncology

Reference28 articles.

1. The economic burden of prostate cancer;Roehrborn;BJU Int,2011

2. GLOBOCAN 2008 (version 1.2);Ferlay,2010

3. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial;J Urol,1997

4. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline;Loblaw;J Clin Oncol,2007

5. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer;Eisenberger;N Engl J Med,1998

Cited by 606 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Intensification With Novel Hormonal Therapy in Castration-Sensitive Prostate Cancer: Patient Identification and Clinical Rationale;Clinical Genitourinary Cancer;2024-12

2. Hormonal Agents in Localized and Advanced Prostate Cancer: Current Use and Future Perspectives;Clinical Genitourinary Cancer;2024-10

3. Comment on Real-world Efficacy and Toxicity Analysis of Abiraterone Acetate versus Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer in Asian Patients;Clinical Genitourinary Cancer;2024-10

4. Efficacy and safety evaluation of androgen deprivation therapy-based combinations for metastatic castration-sensitive prostate cancer: a systematic review and network meta-analysis;British Journal of Cancer;2024-09-02

5. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II—2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer;European Urology;2024-08